Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study of LDGraft In Single Level Lumbar Interbody Fusion (AMBITION)

30. september 2026 opdateret af: Locate Bio Ltd

The objective of the study is to evaluate the safety and effectiveness of LDGraft (investigational device) when applied in a lumbar interbody fusion procedure in the treatment of patients with lumbar Degenerative Disc Disease (DDD).

Studieoversigt

Status

Rekruttering

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

25

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Tbilisi, Georgien, 44600
        • Rekruttering
        • West Georgia Medical Center
        • Kontakt:
          • Study Coordinator
      • Tbilisi, Georgien, 4600
        • Rekruttering
        • JSC Georgian Clinics Kutaisi Referral Hospital
        • Kontakt:
          • Study Coordinator

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

22 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Skeletally mature adults ≥22 and ≤80 years at the time of surgery
  • Willing and able to give written informed consent and comply with study protocol and postoperative management program
  • Degenerative disc disease of the lumbosacral spine in one level requiring fusion confirmed by patient history and radiographic imaging
  • Preoperative Oswestry Disability Index score ≥ 35
  • Participant has not responded to conservative treatment (e.g. medications, injections, physical therapy, etc.) for a period of 6 months

Exclusion Criteria:

  • Previous lumbar spine instrumentation (i.e., anterior disc replacement, interspinous device) or a previous interbody fusion procedure in the lumbar spine
  • More than one level lumbar spine level requiring fusion
  • Three or more contiguous lumbar spine levels requiring decompression
  • Known hypersensitivity or allergy to any components of the study treatments inclusive of hypersensitivity or allergy to any BMP-2 type recombinant proteins or peptides.
  • Pregnant, planning to become pregnant during the follow-up time period, or breast-feeding women
  • Presence of active malignancy
  • Requires bone growth stimulation in the lumbar spine
  • Active local or systemic infection
  • Spondylolisthesis greater than Grade 2 (50% translation)
  • Currently smoking or using nicotine products, including e-cigarette products (e.g., vaping)
  • Any degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis
  • Any medical condition requiring treatment with any drug known to potentially interfere with bone/soft tissue healing or receiving radiation therapy that is expected to continue for the duration of the study
  • Body Mass Index > 40
  • Insulin-dependent diabetes mellitus
  • Osteopenia or osteoporosis of the spine
  • Any secondary causes of osteoporosis or other conditions known to adversely affect osteogenesis
  • Participation in another investigational study within 30 days prior to surgery for investigational devices, or within the last three months for investigational drugs
  • Current or recent history of chemical/alcohol abuse or dependency using standard medical definition of DSM-5 code
  • In the opinion of the investigator, the participant has a behavioral, cognitive, social or medical problem that may interfere with the assessment of the safety or effectiveness of the product
  • Radiographically compromised vertebral bodies at the index level due to current or past trauma
  • Currently a prisoner
  • Involved in active litigation relating to his/her spinal condition or workers compensation claimants.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: LDGraft

LDGraft (b-TCP / rhBMP-2) bone graft substitute

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Secondary Surgical Intervention (SSI)
Tidsramme: 6-month and 12-month follow up

No index level secondary surgical intervention reported

6-month and 12-month follow up
Radiographic Fusion
Tidsramme: 6-month and 12-month follow up

Radiographic fusion derived from bridging bone, angular motion and translational motion assessment via CT

6-month and 12-month follow up
Oswestry Disability Index (ODI) Improvement
Tidsramme: 6-month and 12-month follow up

At least 15 point improvement in ODI compared to baseline

6-month and 12-month follow up
No new or worsening lumbar spine neurological condition
Tidsramme: 6-month and 12-month follow up

No new or worsening lumbar spine neurological condition compared to baseline

6-month and 12-month follow up
No Serious Device Related Adverse Events
Tidsramme: 6-month and 12-month follow up
6-month and 12-month follow up

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Visual Analog Score (VAS) Leg Improvement
Tidsramme: 6-week, 3-month, 6-month and 12-month follow up

20mm improvement compared to baseline

6-week, 3-month, 6-month and 12-month follow up
Visual Analog Score (VAS) Back Improvement
Tidsramme: 6-week, 3-month, 6-month and 12-month follow up

20mm improvement compared to baseline

6-week, 3-month, 6-month and 12-month follow up
Oswestry Disability Index (ODI) Change
Tidsramme: 6-week, 3-month, 6-month and 12 month follow up

Mean change over time intervals

6-week, 3-month, 6-month and 12 month follow up
Visual Analog Score (VAS) Leg Change
Tidsramme: 6-week, 3-month, 6-month and 12-month follow up

Mean change over time intervals

6-week, 3-month, 6-month and 12-month follow up
Visual Analog Score (VAS) Back Change
Tidsramme: 6-week, 3-month, 6-month and 12-month follow up

Mean change over time intervals

6-week, 3-month, 6-month and 12-month follow up
Quality of Life & Satisfaction
Tidsramme: 6-week, 3-month-, 6-month and 12-month follow up

Evaluation of Quality of Life & Satisfaction survey results

6-week, 3-month-, 6-month and 12-month follow up
Radiogrpahic Outcomes
Tidsramme: 6-week, 3-month, 6-month and 12-month follow up

Radiographic outcomes as defined by Image Review Charter

6-week, 3-month, 6-month and 12-month follow up

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. april 2026

Primær færdiggørelse (Anslået)

1. oktober 2027

Studieafslutning (Anslået)

1. december 2027

Datoer for studieregistrering

Først indsendt

22. september 2026

Først indsendt, der opfyldte QC-kriterier

30. september 2026

Først opslået (Faktiske)

5. oktober 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CI-002

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner